Tomáš Vaňásek

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt et al. · The Lancet · 2017 · 883 citations

Gastroenterology, Tight Control Management, Clinical Gastroenterology +3

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

William J. Sandborn, Subrata Ghosh, Julián Panés et al. · Clinical Gastroenterology and Hepatology · 2014 · 295 citations

Inflammation, Chronic Inflammatory Diseases, Anti-inflammatory +9

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 277 citations

Immunology, Clinical Trials, Gastroenterology +7

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Séverine Vermeire, William J. Sandborn, Silvio Danese et al. · The Lancet · 2017 · 197 citations

Inflammation, Autoimmune Disease, Mucosal Immunology +9

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

Satish Keshav, Tomáš Vaňásek, Yaron Niv et al. · PLoS ONE · 2013 · 134 citations · Full text